Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Federico, Giannoni"'
Autor:
Angelo Iacobino, Raffaela Teloni, Carmine Mancone, Francesco Facchiano, Alessandra Di Giamberardino, Cinzia Senatore, Antonio Di Virgilio, Alessio Lanni, Federico Giannoni, Roberto Nisini, Sabrina Mariotti
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The immunization of mice with the sterile culture medium supernatants of Mycobacterium tuberculosis (Mtb) H37Rv permitted the production of several monoclonal antibodies (mAbs) specific for secreted and/or released antigens. Two mAbs bound and immuno
Externí odkaz:
https://doaj.org/article/3353f6aee32145708524c8d34c35662a
Publikováno v:
Microorganisms, Vol 11, Iss 6, p 1511 (2023)
The lungs of tuberculosis (TB) patients contain a spectrum of granulomatous lesions, ranging from solid and well-vascularized cellular granulomas to avascular caseous granulomas. In solid granulomas, current therapy kills actively replicating (AR) in
Externí odkaz:
https://doaj.org/article/d76e6bccba624832b5582ec118d16808
Autor:
Alessio Lanni, Emanuele Borroni, Angelo Iacobino, Cristina Russo, Leonarda Gentile, Lanfranco Fattorini, Federico Giannoni
Publikováno v:
Microorganisms, Vol 10, Iss 7, p 1421 (2022)
Infections caused by Mycobacterium abscessus (Mab), an environmental non-tuberculous mycobacterium, are difficult to eradicate from patients with pulmonary diseases such as cystic fibrosis and bronchiectasis even after years of antibiotic treatments.
Externí odkaz:
https://doaj.org/article/bd1ce9146a7549a8891e7d65287ba116
Autor:
Angelo Iacobino, Giovanni Piccaro, Federico Giannoni, Alessandro Mustazzolu, Lanfranco Fattorini
Publikováno v:
International Journal of Mycobacteriology, Vol 6, Iss 3, Pp 213-221 (2017)
Current tuberculosis (TB) treatment requires 6 months of combination therapy with isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol for active TB and 9 months of INH or 3 months of rifapentine (RFP) + INH for latent TB. The lungs of
Externí odkaz:
https://doaj.org/article/fc1fbf8c7b1044e7a3a8ca906313c7c9
Publikováno v:
Microorganisms, Vol 9, Iss 2, p 255 (2021)
Previous studies on Escherichia coli demonstrated that sub-minimum inhibitory concentration (MIC) of fluoroquinolones induced the SOS response, increasing drug tolerance. We characterized the transcriptional response to moxifloxacin in Mycobacterium
Externí odkaz:
https://doaj.org/article/50192a84aca841a4be894e1b23b67146
Publikováno v:
Applied Sciences, Vol 10, Iss 6, p 2153 (2020)
The control of tuberculosis (TB) is hampered by the emergence of multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) strains, defined as resistant to at least isoniazid and rifampin, the two bactericidal drugs essential for the treatment of th
Externí odkaz:
https://doaj.org/article/9150015be69e4253808890ac442b34a5
Publikováno v:
Microorganisms, Vol 9, Iss 255, p 255 (2021)
Microorganisms
Volume 9
Issue 2
Microorganisms
Volume 9
Issue 2
Previous studies on Escherichia coli demonstrated that sub-minimum inhibitory concentration (MIC) of fluoroquinolones induced the SOS response, increasing drug tolerance. We characterized the transcriptional response to moxifloxacin in Mycobacterium
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ffb423db4ea31a0529a7325aa95315f
https://www.mdpi.com/2076-2607/9/2/255
https://www.mdpi.com/2076-2607/9/2/255
Autor:
Angelo, Iacobino, Giovanni, Piccaro, Manuela, Pardini, Lanfranco, Fattorini, Federico, Giannoni
Publikováno v:
Microorganisms
Previous studies on Escherichia coli demonstrated that sub-minimum inhibitory concentration (MIC) of fluoroquinolones induced the SOS response, increasing drug tolerance. We characterized the transcriptional response to moxifloxacin in Mycobacterium
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::853f5e5d3139005eca2d92f420ba65c2
https://pubmed.ncbi.nlm.nih.gov/33513836
https://pubmed.ncbi.nlm.nih.gov/33513836
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 5, Iss 1, Pp e2013072-e2013072 (2013)
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb), which kills about 2 million people annually. Furthermore, 2 billion people worldwide are latently infected with this organism, with 10% of them reactivating to act
Externí odkaz:
https://doaj.org/article/f28e294cb341487ba163bb4721800f6b
Publikováno v:
European Journal of Public Health. 30
Background The rise in non-tuberculous mycobacteria (NTM) diseases has been reported worldwide, but no major information is known for Italy. The purpose of this pilot study is to release nationwide data on distribution of NTM in our country. Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5388eaf5c15f62670379b03ff9d58d5f
https://doi.org/10.1093/eurpub/ckaa166.843
https://doi.org/10.1093/eurpub/ckaa166.843